The effect of cisplatin dose administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.

5532 Background: Concurrent chemoradiotherapy (Chemo-RT) is superior to RT alone in the treatment of locoregionally advanced nasopharyngeal carcinoma (NPC). There is no published data on minimum dose of cisplatin required to achieve such a survival benefit. This study aims to evaluate the prognostic significance of the total dose of cisplatin administered during chemoradiotherapy in locoregionally advanced NPC patients. Methods: A single-centre retrospective analysis on patients with AJCC Stage II to IVB NPC who were treated with Chemo-RT at the Prince of Wales Hospital between May 1994 and August 2006. Median follow-up = 56.5 months. All patients received intravenous cisplatin at 40mg/m2/ week during a 6-7 week course of RT. Multivariate analysis was performed with covariates including overall stage, TNM stage, age and sex. A planned subgroup analysis based on overall, T and N-stages was performed. Results: 241 patients were included in this analysis (Stages II = 33, III = 109, IV = 99). Median number of...